Drug Profile
Research programme: protein-protein interaction inhibitors - Interprotein Corporation/New York Medical College
Alternative Names: C2 domain-interactive therapeuticsLatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Interprotein Corporation; New York Medical College
- Class Small molecules
- Mechanism of Action Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Fibrosis; Pulmonary hypertension
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in Japan
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in USA
- 28 Oct 2020 No recent reports of development identified for research development in Fibrosis in Japan